新辅助治疗伊匹单抗-尼妥珠单抗优于辅助治疗尼妥珠单抗

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2024-06-14 DOI:10.1038/s41571-024-00916-9

Peter Sidaway

引用次数: 0

摘要

II期试验的数据表明，可切除的黑色素瘤患者有可能从新辅助免疫检查点抑制剂（ICIs）中获益，而那些有主要病理反应（MPR，定义为残留有活力的肿瘤物质≤10%）的患者不太可能需要后续治疗。共有423例可切除的III期黑色素瘤患者被随机分配（1:1）接受2个周期的新辅助伊匹单抗加尼伐单抗治疗，然后进行手术，或手术后接受尼伐单抗辅助治疗。新辅助治疗组中未对新辅助治疗进行MPR的患者接受了尼夫单抗或达拉非尼加曲美替尼（针对BRAFV600E/K突变的患者）的辅助治疗。无事件生存期（EFS）是主要终点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Neoadjuvant ipilimumab–nivolumab superior to adjuvant nivolumab

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.